Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Baber RJ, Panay N, Fenton A (2016) IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19:109–150
2. Burbos N, Musonda P et al (2012) Postmenopausal vaginal bleeding in women using hormone replacement therapy. Menopause Int 18:5–9
3. Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE (2015) Continuous combined estrogen plus progestin and endometrial cancer: the women’s health initiative randomized trial. J Natl Cancer Inst 108:djv350. https://doi.org/10.1093/jnci/djv350
4. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC (2006) A 5‑year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 20:413–423
5. DGGG. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. (2018) Peri- und Menopause – Diagnostik und Therapie. http://www.awmf.org/leitlinien/detail/II/015-062.html. Zugegriffen: 01.04.2020